Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply.

Balar, Arjun V; Kamat, Ashish M; de Wit, Ronald

Balar, Arjun V; Kamat, Ashish M; de Wit, Ronald.

Affiliation

Balar AV; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA. Electronic address: arjun.balar@nyulangone.org.
Kamat AM; MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
de Wit R; Erasmus University Medical Center, Rotterdam, Netherlands.

Lancet Oncol ; 22(9): e380, 2021 09.

Article in En | MEDLINE | ID: mdl-34478664

Subject(s)

Antineoplastic Agents, Immunological; Urinary Bladder Neoplasms; Antibodies, Monoclonal, Humanized/adverse effects; Antineoplastic Agents, Immunological/adverse effects; Humans; Urinary Bladder Neoplasms/drug therapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Antineoplastic Agents, Immunological Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google